These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26451468)

  • 1. Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
    Akgün E; Javed MI; Lunzer MM; Powers MD; Sham YY; Watanabe Y; Portoghese PS
    J Med Chem; 2015 Nov; 58(21):8647-57. PubMed ID: 26451468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance.
    Dutta R; Lunzer MM; Auger JL; Akgün E; Portoghese PS; Binstadt BA
    Arthritis Res Ther; 2018 Jul; 20(1):154. PubMed ID: 30053832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward.
    Cataldo G; Erb SJ; Lunzer MM; Luong N; Akgün E; Portoghese PS; Olson JK; Simone DA
    Neuropharmacology; 2019 Nov; 158():107598. PubMed ID: 30970233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception.
    Akgün E; Javed MI; Lunzer MM; Smeester BA; Beitz AJ; Portoghese PS
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11595-9. PubMed ID: 23798416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice.
    Peterson CD; Kitto KF; Akgün E; Lunzer MM; Riedl MS; Vulchanova L; Wilcox GL; Portoghese PS; Fairbanks CA
    Pain; 2017 Dec; 158(12):2431-2441. PubMed ID: 28891868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heteromer Induction: An Approach to Unique Pharmacology?
    Portoghese PS; Akgün E; Lunzer MM
    ACS Chem Neurosci; 2017 Mar; 8(3):426-428. PubMed ID: 28139906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.
    Le Naour M; Akgün E; Yekkirala A; Lunzer MM; Powers MD; Kalyuzhny AE; Portoghese PS
    J Med Chem; 2013 Jul; 56(13):5505-13. PubMed ID: 23734559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.
    Smeester BA; Lunzer MM; Akgün E; Beitz AJ; Portoghese PS
    Eur J Pharmacol; 2014 Nov; 743():48-52. PubMed ID: 25239072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
    Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
    PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.
    Yuan Y; Arnatt CK; Li G; Haney KM; Ding D; Jacob JC; Selley DE; Zhang Y
    Org Biomol Chem; 2012 Apr; 10(13):2633-46. PubMed ID: 22354464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli.
    Lee YK; Choi DY; Jung YY; Yun YW; Lee BJ; Han SB; Hong JT
    Neuropharmacology; 2013 Apr; 67():57-65. PubMed ID: 23147416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Glia Inhibition and Opioid Receptor Agonism Afford Highly Potent Analgesics without Tolerance.
    Akgün E; Lunzer MM; Portoghese PS
    ACS Chem Neurosci; 2019 Apr; 10(4):2004-2011. PubMed ID: 30110531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers.
    Ma H; Li M; Pagare PP; Wang H; Nassehi N; Santos EJ; Stevens Negus S; Selley DE; Zhang Y
    Bioorg Chem; 2022 Mar; 120():105641. PubMed ID: 35093692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The µ-δ opioid heteromer masks latent pain sensitization in neuropathic and inflammatory pain in male and female mice.
    Inyang KE; George SR; Laumet G
    Brain Res; 2021 Apr; 1756():147298. PubMed ID: 33516809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats.
    Kwiatkowski K; Piotrowska A; Rojewska E; Makuch W; Jurga A; Slusarczyk J; Trojan E; Basta-Kaim A; Mika J
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():68-78. PubMed ID: 26190414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
    Huang B; Wang H; Zheng Y; Li M; Kang G; Barreto-de-Souza V; Nassehi N; Knapp PE; Selley DE; Hauser KF; Zhang Y
    J Med Chem; 2021 Jun; 64(11):7702-7723. PubMed ID: 34027668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR-DOR Heteromer.
    Akgün E; Lunzer MM; Tian D; Ansonoff M; Pintar J; Bruce D; Hawkinson JE; Wilcox GL; Portoghese PS
    Biochemistry; 2021 May; 60(18):1413-1419. PubMed ID: 32930576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model.
    Bober A; Piotrowska A; Pawlik K; Ciapała K; Maciuszek M; Makuch W; Mika J
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.